view counter
Israeli Patent For Cancer Drug
Staff Writer
Photo Galleria: 
Three scientists at the Weizmann Institute of Science in Israel were awarded the patent on a process used in the delivery of the cancer drug Erbitux after a Manhattan federal judge ruled that Aventis and its successor company, ImClone, had copied Weizmann's research and patented it as their own. In a 140-page decision, Judge Naomi Reice Buchwald ruled Monday that the U.S. Patent and Trademark Office must substitute the names of the three Israeli scientists (Michael Sela, Esther Aboud-Pirak and Esther Hurwitz) for the seven now on the patent. The Associated Press quoted lawyers as saying the decision could have a significant impact on the future of Erbitux, the drug made by ImClone, whose founder, Sam Waksal, is now in prison for his role in a stock scandal that also landed Martha Stewart behind bars.

Last Update:

03/07/2012 - 00:25

view counter

Comment Guidelines

The Jewish Week feels comments create a valuable conversation and wants to feature your thoughts on our website. To make everyone feel welcome, we won't publish comments that are profane, irrelevant, promotional or make personal attacks.